Moleculin Biotech is preparing to present encouraging interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory acute myeloid leukemia at the American Society of Hematology annual meeting. The investigational treatment, administered with cytarabine, achieved complete remission rates of 43% and 36% across two dosing groups, compared with 12% for cytarabine plus placebo among the first 45 randomized patients. The findings suggest promising antileukemic activity in a difficult-to-treat patient population, although the interim differences have not established definitive statistical superiority.
The November 4 announcement confirms acceptance of the previously reported data for scientific presentation rather than a new clinical readout. Moleculin has since completed dosing in all 90 patients enrolled in the trial’s initial stage and expects a comprehensive analysis in early 2027. The company also reported no observed signs of cardiotoxicity through the earlier data cutoff, providing preliminary support for the cardiac safety profile of its investigational anthracycline.
How did Annamycin perform against cytarabine in the Phase 2/3 MIRACLE leukemia trial?
The MIRACLE study, also known as MB-108, is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin combined with high-dose cytarabine in adults with relapsed or refractory acute myeloid leukemia. The study’s initial phase compares two Annamycin doses, 190 mg/m² and 230 mg/m², against a control group receiving cytarabine plus placebo. Its primary objective is to evaluate complete remission following a single treatment cycle.
Among the first 45 randomized participants, the 190 mg/m² Annamycin group achieved a complete remission rate of 43%, while the 230 mg/m² group achieved 36%. The corresponding rate in the control arm was 12%, representing an encouraging numerical advantage for both experimental regimens. Composite complete remission rates, which incorporate additional categories of remission, reached 50% and 57% in the respective Annamycin groups, compared with 29% in the control group.
The analysis included all 45 randomized patients on an intent-to-treat basis, without excluding participants from the reported efficacy population. This approach helps preserve the integrity of the randomized comparison.
However, the early analysis did not establish formal statistical significance. The study uses a prespecified sequential statistical design that applies particularly stringent significance thresholds during early interim evaluations.
The results therefore represent promising preliminary efficacy signals rather than confirmation that Annamycin improves remission outcomes. The larger study will determine whether the observed differences remain consistent and meet the required statistical criteria.
Why are complete remission rates important for patients with relapsed or refractory acute myeloid leukemia?
Acute myeloid leukemia is an aggressive blood cancer characterized by abnormal proliferation of immature myeloid cells in the bone marrow. These malignant cells interfere with normal blood production, potentially causing severe anemia, infections and bleeding complications.
Although initial treatment can induce remission, some patients experience disease recurrence or fail to respond adequately. Relapsed or refractory acute myeloid leukemia remains particularly challenging because available treatment options depend on previous therapy, genetic characteristics, overall health and eligibility for stem cell transplantation.
Complete remission generally requires a substantial reduction in detectable leukemia cells alongside recovery of important blood-count parameters. Achieving remission can create opportunities for additional treatment, including potentially curative stem cell transplantation in eligible patients.
Moleculin’s trial specifically evaluates second-line treatment following unsuccessful initial induction therapy. The first interim population included patients previously treated with intensive chemotherapy or venetoclax-based regimens.
Approximately 76% of the initial 45 participants were older than 60, highlighting the relevance of the findings to a population that may face additional treatment-related risks.
An important feature of MIRACLE is that remission is evaluated after one treatment cycle. Historical leukemia trials sometimes permit several cycles before reporting remission, making direct comparisons between studies potentially misleading.
The most informative comparison is therefore between the randomized Annamycin and control groups within MIRACLE itself. Longer follow-up will also be necessary to determine remission durability, subsequent treatment outcomes and survival.
Could Annamycin offer a different cardiac safety profile from conventional anthracyclines?
Annamycin, also known as naxtarubicin, is an investigational liposomal anthracycline designed to treat cancer while addressing limitations associated with conventional medicines in the same class.
Anthracyclines are important components of several chemotherapy regimens, but cumulative exposure can cause cardiac injury. This risk may limit their use in patients who have previously received substantial treatment.
Moleculin developed Annamycin with the objective of reducing susceptibility to certain multidrug resistance mechanisms while limiting cardiotoxicity. Its liposomal formulation is intended to influence drug distribution and exposure.
The company reported that no signs, symptoms or echocardiographic findings suggestive of cardiotoxicity were observed through the MIRACLE interim data cutoff.
An independent data monitoring committee reviewed the interim findings and recommended that the study continue without modifications, retaining both experimental doses and the control arm.
The company has also reported favorable cardiac observations from earlier Annamycin studies, including patients whose cumulative exposure exceeded conventional anthracycline limits.
Nevertheless, the absence of observed cardiotoxicity in a relatively small population does not establish that Annamycin is free from cardiac risk. Uncommon complications and delayed adverse effects may become apparent only with larger patient numbers and prolonged monitoring.
Moleculin expects independent expert review of additional cardiac safety information during the next interim analysis. These findings will be important in determining whether the treatment’s proposed cardiac advantages can be supported by a larger clinical dataset.
Why does the American Society of Hematology presentation matter for Annamycin development?
Moleculin announced that its abstract covering the first MIRACLE interim analysis has been accepted for presentation at the 68th American Society of Hematology Annual Meeting in New Orleans.
The scientific meeting, scheduled for December 12–15, will provide an opportunity for hematology specialists to examine the preliminary remission findings and the trial’s continuing development.
The poster presentation is titled A pivotal Phase 2/3 study of naxtarubicin as second line therapy in patients with AML. The presenting author is Oksana Karnabeda of Arensia Exploratory Medicine.
Acceptance for presentation provides scientific visibility but does not constitute independent confirmation of clinical efficacy or regulatory endorsement.
The study’s monitoring committee recommended continuing all three treatment arms because the available evidence supported further evaluation without identifying a sufficient basis for eliminating either experimental dose.
The next analysis will be particularly informative because the full 90-patient Part A population includes a broader representation of treatment histories than the initial 45-patient group.
Moleculin expects approximately equal representation of patients previously treated with intensive chemotherapy and those treated with venetoclax-based regimens. This could help investigators examine whether earlier treatment exposure influences subsequent Annamycin responses.
However, subgroup findings will require careful interpretation, particularly when patient numbers remain limited.
What comes next for the 90-patient MIRACLE analysis and potential FDA approval?
Moleculin has completed dosing in the initial 90-patient portion of MIRACLE and expects comprehensive Part A results during the first quarter of 2027. The analysis will evaluate efficacy and safety across the larger randomized population and help identify which Annamycin dose should advance into Part B, the subsequent pivotal stage.
The company intends to combine eligible data from the initial and later study stages under the trial’s adaptive design. The complete program is intended to determine whether Annamycin plus cytarabine provides a sufficiently reliable improvement in remission outcomes to support regulatory consideration.
Moleculin has indicated that successful pivotal results could support a New Drug Application submission consistent with discussions with the U.S. Food and Drug Administration. However, the agency has not approved Annamycin for acute myeloid leukemia, and the required evidence remains incomplete. The company must also demonstrate acceptable safety, manufacturing quality and clinically meaningful efficacy before any potential authorization.
For patients with relapsed or refractory acute myeloid leukemia, the initial remission findings provide an encouraging reason to continue investigation. The absence of observed cardiac toxicity adds scientific interest, but both the efficacy and safety profile require confirmation.
The next major assessment will determine whether the promising differences observed among the first 45 patients persist in the complete 90-patient population. Those findings will help shape Annamycin’s pivotal development program and clarify its potential role in future leukemia treatmen
